优化brafv600e突变体转移性NSCLC的恩科非尼和比尼美替尼治疗:高级实践提供者的实用资源

Kelly Goodwin, Kristi Orbaugh, Kirsten Duncan, Erica Stumpf
{"title":"优化brafv600e突变体转移性NSCLC的恩科非尼和比尼美替尼治疗:高级实践提供者的实用资源","authors":"Kelly Goodwin, Kristi Orbaugh, Kirsten Duncan, Erica Stumpf","doi":"10.6004/jadpro.2024.15.8.16","DOIUrl":null,"url":null,"abstract":"<p><p>The <i>BRAF</i> V600E mutation aberrantly activates the mitogen-activated protein kinase (MAPK) pathway, subsequently resulting in uncontrolled cellular proliferation, survival, and dedifferentiation. Approximately 2% of patients with non-small cell lung cancer (NSCLC) have a <i>BRAF</i> V600E mutation. BRAF and MEK inhibitor combination therapy targets two kinases within the MAPK pathway. Encorafenib (Braftovi) and binimetinib (Mektovi) are potent oral inhibitors of BRAF and MEK, respectively. With the recent US Food and Drug Administration approval of encorafenib plus binimetinib, adult patients with <i>BRAF</i> V600E-mutated metastatic NSCLC have an additional treatment option. In the phase II PHAROS study, encorafenib plus binimetinib achieved the primary endpoint of objective response rate by independent review committee and exhibited a manageable safety profile in this patient population. This article provides an overview of the efficacy and safety of encorafenib plus binimetinib and uses a fictional patient case to illustrate the role of advanced practice providers in providing individualized patient care and identifying and managing adverse reactions.</p>","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":"1-17"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715468/pdf/","citationCount":"0","resultStr":"{\"title\":\"Optimizing Treatment of <i>BRAF</i>V600E-Mutant Metastatic NSCLC With Encorafenib and Binimetinib: A Practical Resource for Advanced Practice Providers.\",\"authors\":\"Kelly Goodwin, Kristi Orbaugh, Kirsten Duncan, Erica Stumpf\",\"doi\":\"10.6004/jadpro.2024.15.8.16\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The <i>BRAF</i> V600E mutation aberrantly activates the mitogen-activated protein kinase (MAPK) pathway, subsequently resulting in uncontrolled cellular proliferation, survival, and dedifferentiation. Approximately 2% of patients with non-small cell lung cancer (NSCLC) have a <i>BRAF</i> V600E mutation. BRAF and MEK inhibitor combination therapy targets two kinases within the MAPK pathway. Encorafenib (Braftovi) and binimetinib (Mektovi) are potent oral inhibitors of BRAF and MEK, respectively. With the recent US Food and Drug Administration approval of encorafenib plus binimetinib, adult patients with <i>BRAF</i> V600E-mutated metastatic NSCLC have an additional treatment option. In the phase II PHAROS study, encorafenib plus binimetinib achieved the primary endpoint of objective response rate by independent review committee and exhibited a manageable safety profile in this patient population. This article provides an overview of the efficacy and safety of encorafenib plus binimetinib and uses a fictional patient case to illustrate the role of advanced practice providers in providing individualized patient care and identifying and managing adverse reactions.</p>\",\"PeriodicalId\":94110,\"journal\":{\"name\":\"Journal of the advanced practitioner in oncology\",\"volume\":\" \",\"pages\":\"1-17\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715468/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the advanced practitioner in oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.6004/jadpro.2024.15.8.16\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the advanced practitioner in oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jadpro.2024.15.8.16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

BRAF V600E突变异常激活有丝分裂原活化蛋白激酶(MAPK)途径,随后导致不受控制的细胞增殖、存活和去分化。大约2%的非小细胞肺癌(NSCLC)患者具有BRAF V600E突变。BRAF和MEK抑制剂联合治疗针对MAPK通路中的两种激酶。Encorafenib (Braftovi)和binimetinib (Mektovi)分别是BRAF和MEK的有效口服抑制剂。最近美国食品和药物管理局批准了encorafenib + binimetinib, BRAF v600e突变的转移性NSCLC成年患者有了额外的治疗选择。在PHAROS II期研究中,独立审查委员会认为,encorafenib + binimetinib达到了客观缓解率的主要终点,并且在该患者群体中显示出可管理的安全性。本文概述了encorafenib + binimetinib的疗效和安全性,并使用一个虚构的患者病例来说明高级实践提供者在提供个性化患者护理以及识别和管理不良反应方面的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Optimizing Treatment of BRAFV600E-Mutant Metastatic NSCLC With Encorafenib and Binimetinib: A Practical Resource for Advanced Practice Providers.

The BRAF V600E mutation aberrantly activates the mitogen-activated protein kinase (MAPK) pathway, subsequently resulting in uncontrolled cellular proliferation, survival, and dedifferentiation. Approximately 2% of patients with non-small cell lung cancer (NSCLC) have a BRAF V600E mutation. BRAF and MEK inhibitor combination therapy targets two kinases within the MAPK pathway. Encorafenib (Braftovi) and binimetinib (Mektovi) are potent oral inhibitors of BRAF and MEK, respectively. With the recent US Food and Drug Administration approval of encorafenib plus binimetinib, adult patients with BRAF V600E-mutated metastatic NSCLC have an additional treatment option. In the phase II PHAROS study, encorafenib plus binimetinib achieved the primary endpoint of objective response rate by independent review committee and exhibited a manageable safety profile in this patient population. This article provides an overview of the efficacy and safety of encorafenib plus binimetinib and uses a fictional patient case to illustrate the role of advanced practice providers in providing individualized patient care and identifying and managing adverse reactions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信